Report cover image

Immunogenomics Market

Publisher Grand View Research
Published Mar 02, 2026
Length 120 Pages
SKU # GV21085160

Description

Immunogenomics Market Size, Share & Trends Analysis Report By Type (Instruments, Consumables, Software), By Technology (Polymerase Chain Reaction, Microarray), By Application (Clinical Applications, Research Applications), By End Use, By Region, And Segment Forecasts, 2026 - 2033

Immunogenomics Market Summary

The global immunogenomics market size was estimated at USD 6.32 billion in 2025 and is projected to reach USD 9.82 billion by 2033, expanding at a CAGR of 5.97% from 2026 to 2033. The market growth is being driven by advancements in next-generation sequencing technologies, increasing demand for personalized medicine, and the rising prevalence of immune-related disorders.

Global Immunogenomics Market report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the immunogenomics market on the basis of product type, technology, application, end user, and region.
  • Product Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Instruments
  • Consumables
  • Software
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Microarray
  • Other Technologies
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Clinical Applications
  • Oncology / Cancer Immunotherapy
  • Infectious Diseases & Vaccine Research
  • Autoimmune Disorders
  • Others
  • Research Applications
  • End User Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals & Diagnostic Laboratories
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Other End Users
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
  • Latin America
  • Brazil
  • Argentina
  • Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
Please note The report will be delivered in 2-3 business days upon order notification.

Table of Contents

120 Pages
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.2.1. Product type
1.2.2. Technology
1.2.3. Application
1.2.4. End Use
1.3. Information analysis
1.4. Market formulation & data visualization
1.5. Data validation & publishing
1.6. Information Procurement
1.6.1. Primary Research
1.7. Information or Data Analysis
1.8. Market Formulation & Validation
1.9. Market Model
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Advancements in next-generation sequencing (NGS) and bioinformatics
3.2.1.2. Growing prevalence of immune-related disorders
3.2.2. Market Restraint Analysis
3.2.2.1. Data complexity and interpretation
3.2.2.2. Stringent regulatory requirements
3.2.3. Market Opportunity Analysis
3.2.4. Market Challenge Analysis
3.3. Industry Analysis Tools
3.3.1. Porter's Five Forces Analysis
3.3.2. PESTEL Analysis
Chapter 4. Immunogenomics Market: Product Type Business Analysis
4.1. Product Type Segment Dashboard
4.2. Global Immunogenomics Market Product Type Movement Analysis
4.3. Global Immunogenomics Market Size & Trend Analysis, by Product Type, 2021 to 2033 (USD Million)
4.4. Instruments
4.4.1. Global Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Consumables
4.5.1. Global Consumables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Software
4.6.1. Global Software Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Immunogenomics Market: Technology Business Analysis
5.1. Technology Segment Dashboard
5.2. Global Immunogenomics Market Technology Movement Analysis
5.3. Global Immunogenomics Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
5.4. Next-Generation Sequencing (NGS)
5.4.1. Global Next-Generation Sequencing (NGS) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Polymerase Chain Reaction (PCR)
5.5.1. Global Polymerase Chain Reaction (PCR) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Microarray
5.6.1. Global Microarray Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7. Other Technologies
5.7.1. Global Other Technologies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Immunogenomics Market: Application Business Analysis
6.1. Application Segment Dashboard
6.2. Global Immunogenomics Market Application, Movement Analysis
6.3. Global Immunogenomics Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
6.4. Clinical Applications
6.4.1. Global Clinical Applications Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.2. Oncology / Cancer Immunotherapy
6.4.2.1. Global Oncology / Cancer Immunotherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.3. Infectious diseases & vaccine research
6.4.3.1. Global Infectious Diseases & Vaccine Research Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.4. Autoimmune Disorders
6.4.4.1. Global Autoimmune Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.5. Others
6.4.5.1. Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Research Applications
6.5.1. Global Research Applications Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Immunogenomics Market: End User Business Analysis
7.1. End User Segment Dashboard
7.2. Global Immunogenomics Market End User Movement Analysis
7.3. Global Immunogenomics Market Size & Trend Analysis, by End User, 2021 to 2033 (USD Million)
7.4. Hospitals & Diagnostic Laboratories
7.4.1. Global Hospitals & Diagnostic Laboratories Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Academic & Research Institutes
7.5.1. Global Academic & Research Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Pharmaceutical & Biotechnology Companies
7.6.1. Global Pharmaceutical & Biotechnology Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7. Other End Users
7.7.1. Global Other End Users Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Immunogenomics Market: Regional Estimates & Trend Analysis by Product Type, Technology, Application, & End User.
8.1. Regional Dashboard
8.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
8.3. North America
8.3.1. North America Immunogenomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.3.2. U.S.
8.3.2.1. Key Country Dynamics
8.3.2.2. Competitive Scenario
8.3.2.3. Regulatory Framework
8.3.2.4. U.S. Immunogenomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.3.3. Canada
8.3.3.1. Key Country Dynamics
8.3.3.2. Competitive Scenario
8.3.3.3. Regulatory Framework
8.3.3.4. Canada Immunogenomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.3.4. Mexico
8.3.4.1. Key Country Dynamics
8.3.4.2. Competitive Scenario
8.3.4.3. Regulatory Framework
8.3.4.4. Mexico Immunogenomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4. Europe
8.4.1. Europe Immunogenomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.2. UK
8.4.2.1. Key Country Dynamics
8.4.2.2. Competitive Scenario
8.4.2.3. Regulatory Framework
8.4.2.4. UK Immunogenomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.3. Germany
8.4.3.1. Key Country Dynamics
8.4.3.2. Competitive Scenario
8.4.3.3. Regulatory Framework
8.4.3.4. Germany Immunogenomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.4. France
8.4.4.1. Key Country Dynamics
8.4.4.2. Competitive Scenario
8.4.4.3. Regulatory Framework
8.4.4.4. France Immunogenomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.5. Italy
8.4.5.1. Key Country Dynamics
8.4.5.2. Competitive Scenario
8.4.5.3. Regulatory Framework
8.4.5.4. Italy Immunogenomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.6. Spain
8.4.6.1. Key Country Dynamics
8.4.6.2. Competitive Scenario
8.4.6.3. Regulatory Framework
8.4.6.4. Spain Immunogenomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.7. Denmark
8.4.7.1. Key Country Dynamics
8.4.7.2. Competitive Scenario
8.4.7.3. Regulatory Framework
8.4.7.4. Denmark Immunogenomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.8. Sweden
8.4.8.1. Key Country Dynamics
8.4.8.2. Competitive Scenario
8.4.8.3. Regulatory Framework
8.4.8.4. Sweden Immunogenomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.9. Norway
8.4.9.1. Key Country Dynamics
8.4.9.2. Competitive Scenario
8.4.9.3. Regulatory Framework
8.4.9.4. Norway Immunogenomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5. Asia Pacific
8.5.1. Asia Pacific Immunogenomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.2. Japan
8.5.2.1. Key Country Dynamics
8.5.2.2. Competitive Scenario
8.5.2.3. Regulatory Framework
8.5.2.4. Japan Immunogenomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.3. China
8.5.3.1. Key Country Dynamics
8.5.3.2. Competitive Scenario
8.5.3.3. Regulatory Framework
8.5.3.4. China Immunogenomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.4. India
8.5.4.1. Key Country Dynamics
8.5.4.2. Competitive Scenario
8.5.4.3. Regulatory Framework
8.5.4.4. India Immunogenomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.5. Australia
8.5.5.1. Key Country Dynamics
8.5.5.2. Competitive Scenario
8.5.5.3. Regulatory Framework
8.5.5.4. Australia Immunogenomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.6. Thailand
8.5.6.1. Key Country Dynamics
8.5.6.2. Competitive Scenario
8.5.6.3. Regulatory Framework
8.5.6.4. Thailand Immunogenomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.7. South Korea
8.5.7.1. Key Country Dynamics
8.5.7.2. Competitive Scenario
8.5.7.3. Regulatory Framework
8.5.7.4. South Korea Immunogenomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6. Latin America
8.6.1. Latin America Immunogenomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.2. Brazil
8.6.2.1. Key Country Dynamics
8.6.2.2. Competitive Scenario
8.6.2.3. Regulatory Framework
8.6.2.4. Brazil Immunogenomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.3. Argentina
8.6.3.1. Key Country Dynamics
8.6.3.2. Competitive Scenario
8.6.3.3. Regulatory Framework
8.6.3.4. Argentina Immunogenomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7. MEA
8.7.1. MEA Immunogenomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7.2. South Africa
8.7.2.1. Key Country Dynamics
8.7.2.2. Competitive Scenario
8.7.2.3. Regulatory Framework
8.7.2.4. South Africa Immunogenomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7.3. Saudi Arabia
8.7.3.1. Key Country Dynamics
8.7.3.2. Competitive Scenario
8.7.3.3. Regulatory Framework
8.7.3.4. Saudi Arabia Immunogenomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7.4. UAE
8.7.4.1. Key Country Dynamics
8.7.4.2. Competitive Scenario
8.7.4.3. Regulatory Framework
8.7.4.4. UAE Immunogenomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7.5. Kuwait
8.7.5.1. Key Country Dynamics
8.7.5.2. Competitive Scenario
8.7.5.3. Regulatory Framework
8.7.5.4. Kuwait Immunogenomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Competitive Landscape
9.1. Participant Categorization
9.2. Strategy Mapping
9.3. Company Market Share/ Position Analysis, 2025
9.4. Participant’s Overview
9.4.1. Thermo Fisher Scientific
9.4.1.1. Overview
9.4.1.2. Financial Performance
9.4.1.3. Product Benchmarking
9.4.1.4. Strategic Initiatives
9.4.2. Illumina, Inc.
9.4.2.1. Overview
9.4.2.2. Financial Performance
9.4.2.3. Product Benchmarking
9.4.2.4. Strategic Initiatives
9.4.3. QIAGEN N.V.
9.4.3.1. Overview
9.4.3.2. Financial Performance
9.4.3.3. Product Benchmarking
9.4.3.4. Strategic Initiatives
9.4.4. F. Hoffmann-La Roche Ltd
9.4.4.1. Overview
9.4.4.2. Financial Performance
9.4.4.3. Product Benchmarking
9.4.4.4. Strategic Initiatives
9.4.5. Agilent Technologies, Inc.
9.4.5.1. Overview
9.4.5.2. Financial Performance
9.4.5.3. Product Benchmarking
9.4.5.4. Strategic Initiatives
9.4.6. Bio-Rad Laboratories, Inc.
9.4.6.1. Overview
9.4.6.2. Financial Performance
9.4.6.3. Product Benchmarking
9.4.6.4. Strategic Initiatives
9.4.7. Pacific Biosciences of California, Inc.
9.4.7.1. Overview
9.4.7.2. Financial Performance
9.4.7.3. Product Benchmarking
9.4.7.4. Strategic Initiatives
9.4.8. Oxford Nanopore Technologies plc
9.4.8.1. Overview
9.4.8.2. Financial Performance
9.4.8.3. Product Benchmarking
9.4.8.4. Strategic Initiatives
9.4.9. Eurofins Scientific SE
9.4.9.1. Overview
9.4.9.2. Financial Performance
9.4.9.3. Product Benchmarking
9.4.9.4. Strategic Initiatives
9.4.10. CareDx, Inc.
9.4.10.1. Overview
9.4.10.2. Financial Performance
9.4.10.3. Product Benchmarking
9.4.10.4. Strategic Initiatives

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us